Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Beijing's Genecast Completes $149 Million E Round for Cancer Diagnostics

publication date: Oct 29, 2020

Genecast (Beijing) Technology completed a $149 million Series E financing to develop its second-generation sequencing technology and bioinformatics. Founded in 2014, Genecast has developed a circulating tumor DNA detection technology to provide individualized cancer diagnoses. The E Round was led by China Structural Reform Fund, and joined by Taikang Asset Management, CCB Private Equity Investment Management, Hillhouse Capital’s VC unit GL Ventures and China Renaissance. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital